Novoste Beta-Cath
This article was originally published in The Gray Sheet
Executive Summary
Intravascular beta radiation device premarket approval application is submitted to FDA to treat in-stent restenosis and will receive expedited review by the agency, the firm announces April 17. The PMA is largely based on results of the START (Stents and Radiation Therapy) trial (1"The Gray Sheet" March 20, p. 12)
You may also be interested in...
Novsoste BetaCath Shows Zero Rate Of Late-Stent Thrombosis START Trial
Novoste Corp. appears poised for a smooth path to FDA approval for the BetaCath beta radiation system, given the 0% incidence of late-stent thrombosis in treating patients for in-stent restenosis.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.